Curriculum Vitae
Patrícia Barreto
Identificação
Identificação pessoal
- Nome completo
- Patrícia Susana Correia Lopes Barreto
Nomes de citação
- Barreto, Patrícia
Identificadores de autor
- Ciência ID
- 2313-D0C8-C843
- ORCID iD
- 0000-0002-3375-551X
Endereços de correio eletrónico
- pbarreto@aibili.pt (Profissional)
- patricia.s.barreto@gmail.com (Pessoal)
Moradas
- AIBILI - Associação para a Investigação Biomédica e Inovação em Luz e Imagem. Edifício Prof. Doutor José Cunha-Vaz. Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Coimbra, Portugal (Profissional)
Domínios de atuação
- Ciências Médicas e da Saúde - Ciências da Saúde
Idiomas
| Idioma | Conversação | Leitura | Escrita | Compreensão | Peer-review |
|---|---|---|---|---|---|
| Português (Idioma materno) | |||||
| Inglês | Utilizador proficiente (C2) | Utilizador proficiente (C2) | Utilizador proficiente (C2) | Utilizador proficiente (C2) | |
| Espanhol; Castelhano | Utilizador independente (B1) | Utilizador independente (B1) | Utilizador elementar (A1) | Utilizador independente (B1) |
Formação
| Grau | Classificação | |
|---|---|---|
|
2014 - 2024
Concluído
|
ICH E6 Good Clinical Practice (Outros)
Infonetica Ltd, Reino Unido
|
|
|
2022/07
Concluído
|
EudraVigilance for the electronic transmission of Individual Case Safety Reports (ICSRs) (Outros)
European Medicines Agency, Países Baixos
|
|
|
2022/06
Concluído
|
Extended EudraVigilance Medicinal Product Dictionary (Outros)
European Medicines Agency, Países Baixos
|
|
|
2018/09 - 2022
Em curso
|
Programa de Doutoramento em Ciências da Saúde (Doutoramento)
Especialização em Ciências Biomédicas
Universidade de Coimbra Faculdade de Medicina, Portugal
"Age-Related Macular Degeneration: Genetic Susceptibility, Nutrition and Lifestyle" (TESE/DISSERTAÇÃO)
|
|
|
2016
Concluído
|
Mestrado em Saúde Pública (Mestrado)
Universidade de Coimbra Faculdade de Medicina, Portugal
"Padrão Alimentar, Nutricional e Estilos de Vida Relacionados com a Degenerescência Macular Relacionada com a Idade na População
Portuguesa" (TESE/DISSERTAÇÃO)
|
|
|
1999 - 2005
Concluído
|
Ciências Farmacêuticas (Licenciatura)
Universidade de Coimbra Faculdade de Farmácia, Portugal
|
Percurso profissional
Docência no Ensino Superior
| Categoria Profissional Instituição de acolhimento |
Empregador | |
|---|---|---|
| 2017/09 - 2020/07 | Assistente convidado (Docente Ensino Superior Politécnico) | Instituto Politécnico do Porto, Portugal |
| Instituto Politécnico do Porto Escola Superior de Saúde, Portugal |
Outros
| Categoria Profissional Instituição de acolhimento |
Empregador | |
|---|---|---|
| 2024/10 - Atual | Subdiretora Centro de Ensaios Clínicos/Farmacêutica | Associação para a Investigação Biomédica e Inovação em Luz e Imagem, Portugal |
| Associação para a Investigação Biomédica e Inovação em Luz e Imagem, Portugal | ||
| 2013/12/01 - 2024/10 | Assistente de Direção Centro de Ensaios Clínicos/Farmacêutica | Associação para a Investigação Biomédica e Inovação em Luz e Imagem, Portugal |
| Associação para a Investigação Biomédica e Inovação em Luz e Imagem, Portugal | ||
| 2010/07/01 - 2013/07/01 | Project Leader | Novexem Portugal, Portugal |
| 2009/01/01 - 2013/07/01 | Clinical Research Associate | Novexem Portugal, Portugal |
| 2005/07/01 - 2008/12/31 | Farmacêutica | Farmácia Loureiro, Portugal |
| Farmácia Loureiro, Portugal |
Projetos
Projeto
| Designação | Financiadores | |
|---|---|---|
| 2022 - Atual | Exploratory project – Diabetic Retinopathy: from clinical to cellular phenotyping (C2C)
CEC-012-22
Team member
|
Associação para a Investigação Biomédica e Inovação em Luz e Imagem iCBR - Coimbra Institute for Clinical and Biomedical Research Em curso
|
| 2020 - Atual | Retinal and cognitive dysfunction in type 2 diabetes: unravelling the common pathways and identification of patients at risk
of dementia (RECOGNISED)
ECR-RET-2019-14
NCT04281186
Team member
|
European Union
Em curso
|
| 2018 - Atual | Development of novel clinical endpoints for interventional clinical trials with a regulatory and patient access intention
in patients with intermediate age-related macular degeneration (MACUSTAR)
ECR-AMD-2017-13
NCT03349801
Team member
|
European Union European Federation of Pharmaceutical Industries and Associations Em curso
|
| 2016/04 - Atual | STAR- Development of a Model for Advanced Screening for Timely Treatment of Age-Related Eye Diseases
CEC/008/2016 / STAR
Project Coordinator
|
Associação para a Investigação Biomédica e Inovação em Luz e Imagem
Em curso
|
| 2015 - Atual | Characterization of potential biomarkers of Eye Disease and Vision Loss (EYEMARKER)
4C-2015-08
NCT02500862
Team member
|
Associação para a Investigação Biomédica e Inovação em Luz e Imagem
Em curso
|
| 2022 - 2025 | Diet, medication, and lifestyle in Age-related Macular Degeneration: can the genetic expression be modulated? (AMD LifeGene)
4C-2022-11
NCT05735730
Investigador
|
EURETINA - The European Society of Retina Specialists
Concluído
|
| 2021 - 2024 | 10-year Progression of Diabetic Retinopathy. Identification of Signs and Surrogate Outcomes (PROGRESS 10)
CEC/011/20
NCT04650165
Team member
|
Concluído
|
| 2021 - 2022 | Metabolomics: A Novel Tool for Investigating the Pathogenesis of Age-related Macular Degeneration (AMDMetab)
CEC/010/20
NCT04241536
Team member
|
EURETINA - The European Society of Retina Specialists
Concluído
|
| 2018/07/01 - 2021/12/31 | CORDIS - Characterization of retinal vascular disease in eyes with mild to moderate non-proliferative diabetic retinopathy
in Diabetes type 2, using novel non-invasive imaging methods, in a longitudinal and prospective clinical study with 2 years
of duration.
PTDC/MEC-OFT/30375/2017
Protocol CEC/194/18
Team member
Associação para a Investigação Biomédica e Inovação em Luz e Imagem, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluído
|
| 2017 - 2019 | Progression of Diabetic Retinopathy. Identification of Signs and Surrogate Outcomes (PROGRESS)
CEC/007/2016
NCT03010397
Team member
|
Associação para a Investigação Biomédica e Inovação em Luz e Imagem
Concluído
|
| 2016 - 2017 | Five-year incidence of Age-related Macular Degeneration in the central region of Portugal (AMD Incidence)
Protocol number: 4C-2016-09
NCT02748824
Team member
|
Concluído
|
| 2013 - 2017 | VitaminD3 –Omega3 –Home Exercise –HeALTHy Ageing and Longevity Randomized, double-blind, placebo-controlled, multi-centre
clinical trial (Do-Health)
Do-Health
Pharmacist at the centre (Faculty of Medicine, University of Coimbra)
|
European Commission Seventh Framework Programme for Research and Technological Development
Concluído
|
| 2015 - 2016 | Metabolomics, Genetics and Environment – a novel integrative approach to Age-Related Macular Degeneration
IN0654
Membro da equipa
Fundação para a Ciência e a Tecnologia, Portugal
|
Concluído
|
| 2015 - 2015 | Genotypic and Phenotypic characterization of retinal angiomatous proliferation (RAP) lesions
Protocol number: CEC 006/2015
Membro da equipa
|
Associação para a Investigação Biomédica e Inovação em Luz e Imagem
Concluído
|
Outro
| Designação | Financiadores | |
|---|---|---|
| 2024 - Atual | A phase III, randomized, double-masked, placebo-controlled, multicenter study to evaluate the efficacy, safety, pharmacokinetics,
and pharmacodynamics of satralizumab in participantswith moderate-to-severe thyroid eye disease (SATRA-GO2)
Protocol number: GP44729
NCT06106828
Pharmacist at the Clinical Trials Centre of AIBILI
|
F Hoffmann-La Roche AG
Em curso
|
| 2024 - Atual | A phase III, multicenter, randomized, double-masked, sham-controlled study to investigate the efficacy, safety, pharmacokinetics,
and pharmacodynamics of RO7200220 administered intravitreally in patients with uveitic macular edema (SANDCAT)
Protocol number: GR44278
NCT05642325
Pharmacist at the Clinical Trials Centre of AIBILI
|
F Hoffmann-La Roche AG
Em curso
|
| 2024 - Atual | A Randomized, Double-masked, Multi-center, 3-Arm Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal
EYE103 Compared with Intravitreal ranibizumab (0.5mg) in Participants with Diabetic Macular Edema (BRUNELLO)
Protocol number: EYE-RES-102
NCT06571045
Pharmacist at the Clinical Trials Centre of AIBILI
|
EyeBiotech Ltd. |
| 2023 - Atual | A phase III, multicenter, randomized, double-masked, sham-controlled study to investigate the efficacy, safety, pharmacokinetics,
and pharmacodynamics of RO7200220 administered intravitreally in patients with uveitic macular edema (MEERKAT)
Protocol number: GR44277
NCT05642312
Farmacêutico responsável no centro de ensaios clínicos da AIBILI
|
F Hoffmann-La Roche AG
Em curso
|
| 2023 - Atual | Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema
Secondary to Retinal Vein Occlusion (QUASAR)
Protocol number: 22153
NCT05850520
Pharmacist at the Clinical Trials Centre of AIBILI
|
Bayer Pharma AG Forschung und Entwicklung
Em curso
|
| 2020 - Atual | A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab In Patients with
Diabetic Macular Edema (RHONE-X)
Protocol number: GR41987
NCT04432831
Pharmacist at the Clinical Trials Centre of AIBILI
|
F Hoffmann-La Roche AG
Concluído
|
| 2022 - 2024 | A Phase 2 randomized, placebo-controlled, double-masked proof-of-concept and dose-finding study to investigate the efficacy
and safety of runcaciguat (BAY 1101042) in patients with moderately severe to severe non-proliferative diabetic retinopathy
(NEON)
Protocol number: 20739
NCT04722991
Pharmacist at the Clinical Trials Centre of AIBILI
|
Bayer Pharma AG Forschung und Entwicklung
Concluído
|
| 2021 - 2023 | A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1
to Eylea®, administered intravitreally, in patients with neovascular age-related macular degeneration (MYLIGHT)
Protocol number: CSOK583A1201
NCT04864834
Pharmacist at the Clinical Trials Centre of AIBILI
|
Hexal AG |
| 2019 - 2022 | A phase III, multicentre, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety
of RO6867461 in patients with diabetic macular edema (RHINE)
Protocol number: GR40398
NCT03622593
Pharmacist at the Clinical Trials Centre of AIBILI
|
F Hoffmann-La Roche AG
Concluído
|
| 2019 - 2022 | A two-year, three-arm, randomized, double-masked, multicentre, phase III study assessing the efficacy and safety of brolucizumab
versus aflibercept in adult patients with visual impairment due to diabetic macular edema (KESTREL)
Protocol number: CRTH258B2301
NCT03481634
Pharmacist at the Clinical Trials Centre of AIBILI
|
Novartis AG
Concluído
|
| 2019 - 2022 | A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy andSafety of Conbercept Intravitreal
Injection in Subjects with Neovascular Age-related Macular Subjects with Neovascular Age-related Macular Degeneration (PANDA)
Protocol number: KHB-1801
NCT03577899
Pharmacist at the Clinical Trials Centre of AIBILI
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Desativado
|
| 2019 - 2020 | Randomized,double-masked,placebo-controlled study to evaluate safety,tolerability,pharmacodynamics and pharmacokinetics of
oral BI 1467335 for 12 weeks with a 12 week follow up period in patients with non-proliferative diabetic retinopathy without
center-involved diabetic macular edema (ROBIN)
Protocol number: BI 1386-0012
NCT03238963
Pharmacist at the Clinical Trials Centre of AIBILI
|
Boehringer Ingelheim Europe GmbH
Concluído
|
| 2016 - 2018 | A Two-Year, Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of RTH258 6 mg Versus
Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration (HARRIER)
Protocol number: RTH258-C002
NCT02434328
Pharmacist at the Clinical Trials Centre of AIBILI
|
Alcon Switzerland SA
Concluído
|
| 2016 - 2018 | An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of
three different treatment regimens of 2 mg aflibercept administered by intravitreal injections to subjects with diabetic macular
edema (VIOLET)
Protocol number: 17613
NCT02818998
Pharmacist at the Clinical Trials Centre of AIBILI
|
Bayer SA
Concluído
|
| 2016 - 2018 | Efficacy and safety of Eslicarbazepine acetate (BIA 2-093) as monotheraphy for patients with newly diagnosed partial-onset
seizures: a double- blind, double-dummy, randomized, active-controlled, parallel- group, multicenter clinical study. Open-Label
ESL Extension
Código do protocolo: BIA-2093-311/EXT
NCT02484001
Pharmacist at the Clinical Trials Centre of AIBILI
|
Laboratórios Bial
Concluído
|
| 2015 - 2018 | A phase III, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of lampalizumab
administeredintravitreally to patients with geographic atrophy secondary to age-related macular degeneration (SPECTRI)
Protocol number: GX29185
NCT02247531
Pharmacist at the Clinical Trials Centre of AIBILI
|
F Hoffmann-La Roche AG
Concluído
|
| 2015 - 2018 | A Randomized, Double-masked, Sham-controlled Phase 4 Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept
Monotherapy Compared to Aflibercept with Adjunctive Photodynamic Therapy in patients with Polypoidal Choroidal Vasculopathy
(ATLANTIC)
Protocol number: ECR-AMD-2015-09
NCT02495181
Pharmacist at the Clinical Trials Centre of AIBILI
|
Associação para a Investigação Biomédica e Inovação em Luz e Imagem Bayer SA Concluído
|
| 2016 - 2017 | A randomized, double-masked, placebo-controlled exploratory study to evaluate pharmacodynamics, safety and tolerability of
orally administered BI 1026706 for 12 weeks in patients with mild visual impairment due to center-involved diabetic macular
edema
BI 1320.22
NCT02732951
Pharmacist at the Clinical Trials Centre of AIBILI
|
Boehringer Ingelheim AB
Concluído
|
| 2015 - 2017 | Estudo de intervenção em humanos, multicêntrico e aleatorizado, de suplementação nutricional em doentes com DMRI húmida unilateral
(RETILUT)
Protocol number: THEA-UNAV1/14
Pharmacist at the Clinical Trials Centre of AIBILI
|
Laboratoires Théa SAS
Concluído
|
| 2015 - 2017 | Open-label Phase-4 study to examine the change of vision-related quality of life in subjects with diabetic macular edema (DME)
during treatment with intravitreal injections of 2 mg aflibercept according to EU the first year of treatmentlabel for the
first year of treatment (AQUA)
Protocol number: 17850
NCT02581995
Pharmacist at the Clinical Trials Centre of AIBILI
|
Bayer SA
Concluído
|
| 2015 - 2017 | An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of
2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular
age-related macular degeneration (nAMD) (AZURE)
Protocol number: 16598
NCT02540954
Pharmacist at the Clinical Trials Centre of AIBILI
|
Bayer SA
Concluído
|
| 2014 - 2017 | A 12-month, phase IV, randomized, open label, multicenter study to compare efficacy of 0.5 mg ranibizumab PRN vs 2 mg aflibercept
bimonthly intravitreal injections on retinal thickness stability till month 6 of treatment and explore functional outcomes
up to month 12 in patients with CNV (SALT)
CRFB002ADE23
NCT01958918
Pharmacist at the Clinical Trials Centre of AIBILI
|
Novartis AG
Concluído
|
| 2014 - 2017 | A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous anti PDGF-b pegylated
aptamer in combination with avastin or eylea compared to avastin or eylea monotherapy in subjects with subfoveal neovascular
AMD
Protocol number: OPH1004
NCT01940887
Pharmacist at the Clinical Trials Centre of AIBILI
|
Ophthotech Corporation
Concluído
|
| 2014 - 2016 | Prospective, randomized, multicentre, open label, phase II/III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal
injections plus panretinal photocoagulation vs PRP in monotherapy in the treatment of subjects with high risk proliferative
diabetic retinopathy (PROTEUS)
ECR-RET-2013-05
NCT01941329
Pharmacist at the Clinical Trials Centre of AIBILI
|
Associação para a Investigação Biomédica e Inovação em Luz e Imagem
Concluído
|
| 2014 - 2016 | Intraocular pressure and tolerability Study of Preservative Free Bimatoprost 0.03% Unit Dose or preservative free Latanoprost
0.005% Unit Dose in patients with ocular hypertension or glaucoma: a randomized, single masked, 3-month cross-over, Investigator-led,
European multicenter Trial (SPORT)
ECR-GLC-2013-06
NCT01975714
Pharmacist at the Clinical Trials Centre of AIBILI
|
Associação para a Investigação Biomédica e Inovação em Luz e Imagem
Concluído
|
| 2013 - 2016 | A multicenter,double-blind,double-dummy,follow-up study evaluating long-term safety of lacosamide (200 to 600mg/day) in comparison
with carbamazepine (400 to 1200mg/day), used as monotherapy in subjects with partial-onset or generalized tonic-clonic seizures>16
years of age coming from SP0993 study
Protocol number: SP0994
NCT01465997
Pharmacist at the Clinical Trials Centre of AIBILI
|
UCB Pharma AS
Concluído
|
| 2013 - 2016 | Efficacy and safety of Eslicarbazepine acetate (BIA 2-093) as monotheraphy for patients with newly diagnosed partial-onset
seizures: a double- blind, double-dummy, randomized, active-controlled, parallel- group, multicenter clinical study
Protocol number: BIA-2093-311
NCT02484001
Pharmacist at the Clinical Trials Centre of AIBILI
|
Laboratórios Bial
Concluído
|
| 2014 - 2015 | A non-randomised, open-label, multicenter phase 4 pilot study of the effect and safety of Iluvien® in chronic diabetic macular
edema patients considered insufficiently responsive to available therapie with or without intravitreal corticosteroid therapy
(RESPOND)
4C-2014-06
NCT02359526
Pharmacist at the Clinical Trials Centre of AIBILI
|
Associação para a Investigação Biomédica e Inovação em Luz e Imagem
Concluído
|
| 2014 - 2015 | A 12-month, phase IIIb, randomized, visual acuity assessor-masked, multicenter study assessing the efficacy and safety of
ranibizumab 0.5mg in treat and extend regimen compared to monthly regimen, in patients with neovascular age-related macular
degeneration (TREND)
CRFB002A2411
NCT01948830
Pharmacist at the Clinical Trials Centre of AIBILI
|
Novartis International AG
Concluído
|
| 2014 - 2015 | Assessment of Anatomical and Functional Outcomes in Patients Treated with Ocriplasmin for Vitreomacular Traction/Symptomatic
Vitreomacular Adhesion (JETREA)
M-13-056
NCT02035748
Pharmacist at the Clinical Trials Centre of AIBILI
|
Alcon AG
Concluído
|
| 2013 - 2015 | Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy (EUROCONDOR)
Protocol number: 4C-2011-02
NCT01726075
Pharmacist at the Clinical Trials Centre of AIBILI
|
BCN Peptides
Concluído
|
| 2013 - 2015 | A randomised, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s
Disease Uveitis (EYEGUARD B)
Protocol number: CL3-78989-002
NCT01965145
Pharmacist at the Clinical Trials Centre of AIBILI
|
Les Laboratoires Servier SAS
Concluído
|
| 2013 - 2015 | A randomized, double-masked, placebo-controlled study of the safety and efficacy of Gevokizumab in the treatment of active
non-infectious intermediate, posterior, or pan- uveitis (EYEGUARD A)
Protocol number: CL3-78989-005
NCT01684345
Pharmacist at the Clinical Trials Centre of AIBILI
|
Les Laboratoires Servier SAS
Concluído
|
| 2013 - 2015 | Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion (BRIGHTER)
Protocol number: CRFB002E2402
NCT01599650
Pharmacist at the Clinical Trials Centre of AIBILI
|
Novartis AG
Concluído
|
| 2013 - 2015 | A 24-month, phase IIIb, randomized, double-masked, multicenter study assessing the efficacy and safety of two treatment regimens
of 0.5 mg ranibizumab intravitreal injections guided by functional and/or anatomical criteria, in patients with neovascular
age-related macular degeneration (OCTAVE)
Protocol number: CRFB002A2405
NCT01780935
Pharmacist at the Clinical Trials Centre of AIBILI
|
Novartis International AG
Concluído
|
| 2013 - 2015 | A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab
intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal
neovascularization (MINERVA)
Protocol number: CRFB002G2301
NCT01840410
Pharmacist at the Clinical Trials Centre of AIBILI
|
Novartis Pharma AG
Concluído
|
| 2013 - 2015 | A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis
in Parkinson’s Disease
Protocol Number: ACP-103-015
NCT00658567
Pharmacist at the Clinical Trials Centre of AIBILI
|
Acadia Pharmaceuticals Inc
Concluído
|
| 2013 - 2015 | Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus placebo, in co-administration with donepezil (10 mg/day)
in patients with moderate Alzheimer’s Disease. A 24-week international, multi-centre, randomised, double-blind,placebo-controlled
phase IIb study
Protocol number: CL2-38093-012
2011-005862-40
Pharmacist at the Clinical Trials Centre of AIBILI
|
Les Laboratoires Servier SAS Recherche & Développement
Concluído
|
| 2013 - 2015 | Multicenter,double-blind,randomized,controlled study comparing the efficacy/safety of lacosamide (200-600 mg/day) to controlled
release carbamazepine (400-1200 mg/day), used as monotherapy in subjects newly/recently diagnosed with epilepsy with partial-onset
or generalized tonic-clonic seizures
Protocol Number: SP0993
NCT01243177
Pharmacist at the Clinical Trials Centre of AIBILI
|
UCB Pharma AS
Concluído
|
| 2013 - 2015 | A Randomized, Double-masked, placebo-controlled study of the Safety and Efficacy of Gevokizumab in the treatment of subjects
with non-infectious intermediate, posterior, or pan- uveitis currently controlled with systemic treatment (EYEGUARD C)
Protocol number: CL3-78989-006
NCT01747538
Pharmacist at the Clinical Trials Centre of AIBILI
|
Les Laboratoires Servier SAS
Concluído
|
| 2013 - 2015 | Efficacy and safety of BIA 9-1067 in idiopathic Parkinson’s disease patients with “wearing-off” phenomenon treated with levodopa
plus a dopa decarboxylase inhibitor:double-blind,randomised,placebo-and active-controlled,parallel-group,multicentre study
(BIPARK II)
Protocol number: BIA-91067-302
NCT01568073
Pharmacist at the Clinical Trials Centre of AIBILI
|
Laboratórios Bial
Concluído
|
| 2013 - 2014 | Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein
Occlusion (CRYSTAL)
Protocol number: CRFB002E2401
NCT01535261
Pharmacist at the Clinical Trials Centre of AIBILI
|
Novartis AG
Concluído
|
| 2013 - 2014 | Multicenter, randomized, double-masked, 3 arms, vehicle controlled, 4-month phase 3 trial with a 8 month safety follow up
period to evaluate the efficacy and safety of 2 dosing regimen of NOVA22007 1mg/ml eye drops, administered 4 times/day in
pediatric patients with active severe vernal (VEKTIS)
Protocol number: NVG09B113
NCT01751126
Pharmacist at the Clinical Trials Centre of AIBILI
|
Santen SA
Concluído
|
Produções
Publicações
| Artigo em revista |
|
| Recurso online |
|
| Tese / Dissertação |
|
Atividades
Apresentação oral de trabalho
| Título da apresentação | Nome do evento Anfitrião (Local do evento) |
|
|---|---|---|
| 2024/11/22 | Uncovering statins and genetics in age-related macular degeneration | Congresso Nacional dos Farmacêuticos 2024
Ordem dos farmacêuticos (Lisboa, Portugal)
|
| 2024/11/05 | Ensaios clínicos da iniciativa do investigador e AIBILI: um caso de sucesso | O Farmacêutico e os ensaios clínicos; novas perspectivas
Ordem dos Farmacêuticos
|
| 2024/09/19 | Lifestyle, genetic risk and age-related macular degeneration – The Coimbra Eye Study | 24 th EURETINA Congress 2024
EURETINA (Barcelona, Espanha)
|
| 2024/07/10 | Genetics & statins in the progression for age-related macular degeneration | IV Reunião dos Grupos de Investigação da AIBILI
AIBILI (Coimbra, Portugal)
|
| 2024/05/07 | Uncovering statins with genetics in age-related macular degeneration | ARVO 2024
ARVO (Seattle, Estados Unidos)
|
| 2024/05/07 | Association between the genetic risk score and extramacular drusen in an age-related macular degeneration cohort - The Coimbra Eye Study | ARVO 2024
ARVO (Seattle, Estados Unidos)
|
| 2023/12/01 | Statins and genetics in the risk of progression of age-related macular degeneration. The Coimbra Eye Study | 66º Congresso Português de Oftalmologia
Sociedade Portuguesa de Oftalmologia (Vilamoura, Portugal)
|
| 2023/10/07 | Statins and genetics in the risk of progression of age-related macular degeneration - The Coimbra Eye Study | 23 rd EURETINA Congress 2023
EURETINA (Amesterdão, Países Baixos)
|
| 2023/05/24 | Age-related macular degeneration: the interaction of genetics, Mediterranean diet and statins | III reunião dos Grupos de Investigação da AIBILI
AIBILI (Coimbra, Portugal)
|
| 2022/12/01 | Genetics and the Mediterranean diet: what is the risk for age-related macular degeneration? | 65º Congresso Português de Oftalmologia
Sociedade Portuguesa de Oftalmologia (Coimbra, Portugal)
|
| 2022/09/03 | Association of genetics and the adherence to the mediterranean diet: the risk for age-related macular degeneration | 22 nd EURETINA Congress 2022
EURETINA (Hamburgo, Alemanha)
|
| 2022/07/20 | Cluster Analysis and Genetic Risk Score in Age-related Macular Degeneration - The Coimbra Eye Study | The 17th Conference of the International Federation of Classification Societies
(Porto, Portugal)
|
| 2022/05/11 | Association of genetics and the adherence to the Mediterranean diet: the risk for age-related macular degeneration | ARVO 2022 |
| 2021/05 | Genetic characterization of a Portuguese age-related macular degeneration population | ARVO 2021
Association for Research in Vision and Ophthalmology (San Francisco & on line, Estados Unidos)
|
| 2021/05 | Characterization of risk phenotypes of type 2 diabetes nonproliferative retinopathy | ARVO 2021
Association for Research in Vision and Ophthalmology (San Francisco & online, Estados Unidos)
|
| 2021/05 | Characterization of one-year progression in risk phenotypes of diabetic retinopathy | ARVO 2021
Association for Research in Vision and Ophthalmology (San Francisco & online, Estados Unidos)
|
| 2021/05 | Common and rare genetic risk variants for Age-related Macular Degeneration progression in the Coimbra Eye Study. | ARVO 2021
Association for Research in Vision and Ophthalmology (São Francisco & Online, Estados Unidos)
|
| 2020/07/10 | Surgimento das Boas Práticas Clínicas | Workshop em Boas Práticas Clínicas | Formato webinar
AIBILI
|
| 2019/12/06 | Age-related macular degeneration prevalence and staging by color fundus photography vs multimodal imaging. The Coimbra Eye Study | 62.º Congresso Português de Oftalmologia
SPO (Portugal)
|
| 2019/12 | Estudo CORDIS - um ensaio longitudinal, prospetivo e intervencional numa população de doentes diabéticos tipo 2 com retinopatia ligeira a moderada | Sociedade Portuguesa de Oftalmologia - SPO
SPO (Portugal)
|
| 2018/03 | Estudo sobre a incidência da Degenerescência Macular Relacionada com a Idade aos cinco anos na região centro de Portugal. | XIX Congresso Nacional de Ortoptistas
Associação Portuguesa de Ortoptistas (Espinho, Portugal)
|
| 2017/09 | Food and Nutritional Pattern and Lifestyle related to Age-Related Macular Degeneration in Portugal. | 17 th EURETINA Congress 2017
EURETINA (Barcelona, Espanha)
|
| 2017/09 | Multimodal evaluation of the fellow eye of patients with retinal angiomatous proliferation | 17 th EURETINA Congress 2017
EURETINA (Barcelona, Espanha)
|
| 2016/12 | Age-related Macular Degeneration: an association with physical activity and lifestyle | 59º Congresso Português e Oftalmologia
Sociedade Portuguesa de Oftalmologia (Coimbra, Portugal)
|
| 2016/12 | Espessura da coróide na Degenerescência Macular relacionada com a Idade: a influência dos drusens reticulares. | 59º Congresso Português e Oftalmologia
Sociedade Portuguesa de Oftalmologia (Coimbra, Portugal)
|
| 2016/12 | Terapêutica no Edema Macular Diabético. Que Futuro? | 59º Congresso Português e Oftalmologia
Sociedade Portuguesa de Oftalmologia (Coimbra, Portugal)
|
| 2016/11/09 | CEC - Clinical Trials Centre - AIBILI Clinical Trials in Ophthalmology | Conferência APIFARMA 2016 "Investigação Clínica - Do Compromisso à Acção
APIFARMA (Lisboa, Portugal)
|
| 2016/10 | The Role of Adherence to a Mediterranean Diet and Lifestyle Risk Factors in AMD - The Coimbra Eye Study. | American Academy of Ophthamology
American Academy of Ophthamology (Chicago, Estados Unidos)
|
| 2016/10 | The Role of Reticular Pseudodrusen on Choroidal Thickness With Swept Source OCT | American Academy of Ophthamology;
American Academy of Ophthamology; (Chicago, Estados Unidos)
|
| 2008/05 | Mental Health | 10th Congress of Young Pharmacists
(Opava, República Checa)
|
| 2008/05 | Pharmaceutical Education in Portugal | 10th Congress of Young Pharmacists
(Opava, República Checa)
|
Organização de evento
| Nome do evento Tipo de evento (Tipo de participação) |
Instituição / Organização | |
|---|---|---|
| 2023/06/01 - 2023/06/03 | 33 rd EAsDEC Conference 2023 (2023/06/01 - 2023/06/03) | Associação para a Investigação Biomédica e Inovação em Luz e Imagem, Portugal |
Participação em evento
| Descrição da atividade Tipo de evento |
Nome do evento Instituição / Organização |
|
|---|---|---|
| 2025/03/06 - 2025/03/08 | 21º Congresso Português de Diabetes |
Sociedade Portuguesa de Diabetologia, Portugal
|
| 2024/12/05 - 2024/12/05 | Investigação clínica: oportunidades do novo modelo colaborativo em contexto das ULS | |
| 2024/10/22 - 2024/10/22 | Acção CAPACITAR: Farmácia Hospitalar e a Gestão do Medicamento Experimental | Acção CAPACITAR
AICIB, Portugal
|
| 2024/04/09 - 2024/04/09 | Revisão sistemática e meta-análise | Revisão sistemática e meta-análise
Universidade de Coimbra Instituto de Investigação Interdisciplinar, Portugal
|
| 2024/02/21 - 2024/02/21 | Acção CAPACITAR: Gestão de contratos de ensaio clínico
Oficina (workshop)
|
AICIB, Portugal
|
| 2023/10/21 - 2023/10/21 | Acção CAPACITAR: Actividades de coordenação de Investigação clínica |
AICIB, Portugal
|
| 2023/06/01 - 2023/06/03 | 33rd EAsDEC Conference 2023 |
Associação para a Investigação Biomédica e Inovação em Luz e Imagem, Portugal
|
| 2023/05/05 - 2023/05/05 | À mesa com saúde: organized dinner commented by chefs, scientists and clinicians, which aim to address diseases and their prevention through diet. | À mesa com saúde
iCBR - Coimbra Institute for Clinical and Biomedical Research, Portugal
|
| 2023 - 2023 | Interaction between genetics and the adherence to the Mediterranean diet: the risk for age-related macular degeneration. | 46th Macula Society Annual Meeting
Macula Society, Estados Unidos
|
| 2023 - 2023 | Statins and genetics in the risk of progression of age-related macular degeneration | 48th Macula Society Annual Meeting
Macula Society, Estados Unidos
|
| 2022/06/09 - 2022/06/09 | Urinary Mass Spectrometry Metabolomic Profiles in Age-related Macular Degeneration (AMD) | 45th Annual Macula Society Meeting
Macula Society, Estados Unidos
|
| 2022/05/09 - 2022/05/09 | Phenotypic expression of CFH rare variants in AMD patients | The 45th Annual Macula Society Meeting
Macula Society, Estados Unidos
|
| 2020/10/24 - 2020/10/24 | 15th EVICR.net Members Meeting 2020 | 15th EVICR.net Members Meeting 2020
European Vision Institute Clinical Research Network , Portugal
|
| 2020/10/02 - 2020/10/04 | EURETINA 2020 | EURETINA 2020
EURETINA - The European Society of Retina Specialists, Irlanda
|
| 2020/07/10 - 2020/07/10 | Workshop em Boas Práticas Clínicas | Workshop em Boas Práticas Clínicas
Associação para a Investigação Biomédica e Inovação em Luz e Imagem, Portugal
|
| 2019/10/24 - 2019/10/25 | 14th EVICR.net Meeting |
EVICR Network, Portugal
|
| 2019/06/12 - 2019/06/12 | Clinical Research at a glance | Clinical Research at a glance
iCBR - Coimbra Institute for Clinical and Biomedical Research, Portugal
|
| 2019 - 2019 | Human Plasma Metabolomics in Age-related Macular Degeneration – Meta-Analysis of Two Distinct Cohorts | 42nd Annual Macula Society Meeting
Macula Society, Estados Unidos
|
| 2017/04/07 - 2017/04/07 | Ciclo de Divulgação: Update on OCT Angiography |
Associação para a Investigação Biomédica e Inovação em Luz e Imagem, Portugal
|
| 2016/12/05 - 2016/12/05 | Lançamento do Registo Nacional de Estudos Clínicos |
Infarmed Autoridade Nacional do Medicamento e Produtos de Saúde IP, Portugal
|
| 2016/11/09 - 2016/11/09 | Ciclo de Conferências "Saber investir, saber inovar. Inovação clínica - do compromisso à acção" |
Associação Portuguesa da Indústria Farmacêutica, Portugal
|
| 2016/11/04 - 2016/11/04 | II Encontro Regional de Farmacovigilância |
Associação para a Investigação Biomédica e Inovação em Luz e Imagem, Portugal
|
| 2016/02/13 - 2016/02/13 | Reunião Científica do GER (Grupo de Estudos da Retina) |
Sociedade Portuguesa de Oftalmologia, Portugal
|
| 2015/11/26 - 2015/11/27 | 10th EVICR.net Members Meeting |
EVICR Network, Portugal
|
| 2014/11/16 - 2014/11/18 | 9th EVICR.net Members Meeting |
EVICR Network, Portugal
|
Júri de grau académico
| Tema Tipo de participação |
Nome do candidato (Tipo de grau) Instituição / Organização |
|
|---|---|---|
| 2024/09/30 | Fragilidade de ensaios clínicos com Nirmatrelvir-Ritonavir (Paxlovid) em doentes com COVID -19 não hospitalizados: revisão
sistemática
Arguente principal
|
Raquel Duarte Gomes (Mestrado)
Universidade de Coimbra Faculdade de Farmácia, Portugal
|
Curso / Disciplina lecionado
| Disciplina | Curso (Tipo) | Instituição / Organização | |
|---|---|---|---|
| 2025/04/08 - 2025/04/08 | O que faz um farmacêutico num ensaio clínico | Ciências Farmacêuticas (Licenciatura) | Universidade de Coimbra Faculdade de Farmácia, Portugal |
| 2024/12/02 - 2024/12/10 | Fundamentals of Clinical Research and Clinical Trials | Ortóptica (Licenciatura) | Instituto Politécnico do Porto, Portugal |
| 2024/10/25 - 2024/10/25 | Fundamentals of Clinical Research | Farmacologia Aplicada (Mestrado) | Universidade de Coimbra Faculdade de Farmácia, Portugal |
| 2024/10/23 - 2024/10/23 | Fundamentals of Clinical Research | Mestrado em Investigação Biomédica (Mestrado) | Universidade de Coimbra Faculdade de Medicina, Portugal |
| 2024/03/14 - 2024/03/14 | Ensaio Clínico | Ortóptica (Licenciatura) | Instituto Politécnico do Porto Escola Superior de Saúde, Portugal |
| 2023/11/03 - 2023/11/03 | Fundamentals of Clinical Research | Farmacologia Aplicada (Mestrado integrado) | Universidade de Coimbra Faculdade de Farmácia, Portugal |
| 2023/10/31 - 2023/10/31 | Fundamentals of Clinical Research | Mestrado em Investigação Clínica (Mestrado) | Universidade de Coimbra Faculdade de Medicina, Portugal |
| 2023/03/15 - 2023/03/22 | Processo de Ensaio Clínico | Ortóptica (Licenciatura) | Instituto Politécnico do Porto Escola Superior de Saúde, Portugal |
| 2022/10/18 - 2022/10/18 | Clinical Research | Mestrado em Investigação Biomédica (Mestrado) | Universidade de Coimbra Faculdade de Medicina, Portugal |
| 2022/03/23 - 2022/03/30 | Processo de Ensaio Clínico | Ortóptica (Licenciatura) | Instituto Politécnico do Porto Escola Superior de Saúde, Portugal |
| 2022/03/14 - 2022/03/14 | Ensaios Clínicos | Ortóptica (Licenciatura) | Instituto Politécnico do Porto Escola Superior de Saúde, Portugal |
| 2022 - 2022 | Building a study protocol: rationale, hypothesis, design, significant sample calculation | Curso de Investigação Clínica para Oftalmologistas (Outros) | Sociedade Portuguesa de Oftalmologia, Portugal |
| 2020/10/28 - 2020/10/28 | Workshop on clinical research | Mestrado em Investigação Biomédica (Mestrado) | Universidade de Coimbra Faculdade de Medicina, Portugal |
| 2019/10/28 - 2019/10/28 | Fundamentals on Clinical Research | Mestrado em Investigação Biomédica (Mestrado) | Universidade de Coimbra Faculdade de Medicina, Portugal |
| 2019/05/31 - 2019/05/31 | Seminário/ Investigação Translacional em Oftalmologia. | Ortóptica (Licenciatura) | Instituto Politécnico do Porto Escola Superior de Saúde, Portugal |
| 2019/03/25 - 2019/03/25 | Clinical Research no âmbito da Unidade Curricular de Desenvolvimento Farmacêutico, Licenciatura em Ciências Biomédicas | Biomedicina Farmacêutica (Licenciatura) | Universidade de Aveiro Departamento de Ciências Médicas, Portugal |
| 2018/03/16 - 2018/03/16 | Seminário - Investigação Translacional em Oftalmologia. | Ortóptica (Licenciatura) | Instituto Politécnico do Porto Escola Superior de Saúde, Portugal |
| 2016/05/21 - 2016/05/21 | Investigação Clínica – a perspetiva do Investigador e contextualização legal. | Ortóptica (Licenciatura) | Instituto Politécnico do Porto Escola Superior de Saúde, Portugal |
Membro de associação
| Nome da associação | Tipo de participação | |
|---|---|---|
| 2024 - Atual | Member of the Group of Interest in Clinical Trials of the Portuguese Pharmaceutical Board | Member |
| 2023 - Atual | EURETINA - European Society of Retina Specialists | Member |
| 2005/08 - Atual | Portuguese Pharmaceutical Board (Ordem dos Farmacêuticos) | Member |
Distinções
Prémio
| 2024 | Prémio Plácido
Sociedade Portuguesa de Oftalmologia, Portugal
|
| 2023 | Prémio Plácido
Sociedade Portuguesa de Oftalmologia, Portugal
|
| 2022 | Prémio Plácido |
| 2022 | Melhor Artigo de Retina
Sociedade Portuguesa de Oftalmologia, Portugal
|
| 2021 | Prémio Plácido
Sociedade Portuguesa de Oftalmologia, Portugal
|
| 2021 | Prémio de Melhor Poster de Investigação Clínica
Sociedade Portuguesa de Diabetologia, Portugal
|